Nephrotic Syndrome in Adults

1. Clinical Overview

Nephrotic syndrome is a clinical syndrome characterized by massive proteinuria leading to hypoalbuminaemia, oedema, and hyperlipidaemia. It represents glomerular dysfunction with loss of the filtration barrier's selective permeability. [1,2]

Unlike nephritic syndrome (which presents with haematuria, hypertension, and AKI), nephrotic syndrome is defined by protein loss as the cardinal feature, with resultant metabolic and haemostatic complications. [3]

The Classical Diagnostic Tetrad

1. Heavy Proteinuria: > 3.5 g/24h (or urine protein:creatinine ratio > 300-350 mg/mmol)
2. Hypoalbuminaemia: Serum albumin less than 30 g/L (often less than 25 g/L)
3. Oedema: Peripheral, periorbital, or generalized (anasarca)
4. Hyperlipidaemia: Elevated cholesterol and triglycerides

Image: The Nephrotic Tetrad

Image

Note: While the classical definition requires only proteinuria, hypoalbuminaemia, and oedema, hyperlipidaemia is present in > 90% of cases and contributes to long-term cardiovascular risk. [4]

Epidemiology

• Adult incidence: 3 per 100,000 per year in Western populations [5]
• Age distribution: Bimodal - children (minimal change disease predominates) and adults > 60 years (membranous nephropathy predominates) [6]
• Gender: Slight male predominance (1.5:1) in most primary glomerulopathies [7]
• Ethnic variation: FSGS is 3-4 times more common in individuals of African descent [8]

---

2. Molecular Pathophysiology

The Glomerular Filtration Barrier

The glomerular filtration barrier consists of three layers: [9]

1. Fenestrated endothelium: Prevents cellular elements from crossing
2. Glomerular basement membrane (GBM): Size-selective barrier (prevents molecules > 100 kDa)
3. Podocyte layer with foot processes: Charge-selective barrier (prevents negatively charged proteins like albumin)

Image: Podocyte Ultrastructure

Image

┌─────────────────────────────────────────────────────────────────────────────┐
│                    NEPHROTIC SYNDROME PATHOPHYSIOLOGY                       │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                 GLOMERULAR FILTRATION BARRIER DAMAGE                │   │
│   │                                                                     │   │
│   │  PRIMARY INJURY MECHANISMS:                                         │   │
│   │  • Podocyte foot process effacement (loss of slit diaphragm)       │   │
│   │  • Loss of negative charge barrier (heparan sulfate degradation)   │   │
│   │  • Basement membrane thickening or disruption                      │   │
│   │  • Mesangial matrix expansion                                      │   │
│   │                                                                     │   │
│   │  MOLECULAR TARGETS:                                                 │   │
│   │  • Nephrin (NPHS1) - slit diaphragm protein                        │   │
│   │  • Podocin (NPHS2) - foot process structural protein               │   │
│   │  • α-actinin-4 - cytoskeletal protein                              │   │
│   │  • PLA2R (M-type phospholipase A2 receptor) - in membranous       │   │
│   │                                                                     │   │
│   │  RESULT: Massive albumin leak into urinary space (> 3.5g/day)      │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                 MASSIVE PROTEINURIA (> 3.5g/day)                     │   │
│   │                                                                     │   │
│   │  • Hepatic albumin synthesis increases 2-3 fold                    │   │
│   │  • But cannot compensate for urinary losses (up to 20-30g/day)     │   │
│   │  • HYPOALBUMINAEMIA (less than 30 g/L, often less than 20 g/L)                       │   │
│   │  • Loss of albumin-bound substances:                               │   │
│   │    - Thyroid hormones (T3, T4)                                     │   │
│   │    - Vitamin D binding protein                                     │   │
│   │    - Trace elements (zinc, copper)                                 │   │
│   │    - Drugs (highly protein-bound medications)                      │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│               ┌────────────────────┴─────────────────────┐                  │
│               ↓                                          ↓                  │
│   ┌───────────────────────────┐          ┌──────────────────────────┐       │
│   │ "UNDERFILL" HYPOTHESIS    │          │ "OVERFILL" HYPOTHESIS    │       │
│   │ (Historical)              │          │ (Now Dominant)           │       │
│   ├───────────────────────────┤          ├──────────────────────────┤       │
│   │ • Low plasma oncotic      │          │ • Primary renal sodium   │       │
│   │   pressure                │          │   retention              │       │
│   │ • Fluid shifts to inter-  │          │ • ENaC channel over-     │       │
│   │   stitium                 │          │   activation in collect- │       │
│   │ • Intravascular volume ↓  │          │   ing duct               │       │
│   │ • RAAS activation         │          │ • Independent of plasma  │       │
│   │ • Secondary Na+ retention │          │   volume status          │       │
│   │                           │          │ • Explains hypertension  │       │
│   │ LIMITED EVIDENCE          │          │   in many patients       │       │
│   └───────────────────────────┘          └──────────────────────────┘       │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │                 CLINICAL SEQUELAE                                   │   │
│   ├─────────────────────────────────────────────────────────────────────┤   │
│   │ 1. OEDEMA (gravity-dependent: ankles → legs → sacrum → anasarca)   │   │
│   │                                                                     │   │
│   │ 2. HYPERLIPIDAEMIA                                                  │   │
│   │    • Hepatic lipoprotein synthesis ↑ (compensatory response)       │   │
│   │    • Lipoprotein lipase activity ↓ (loss in urine)                 │   │
│   │    • Total cholesterol > 7 mmol/L typical                           │   │
│   │    • LDL ↑, VLDL ↑, HDL may be ↓                                   │   │
│   │                                                                     │   │
│   │ 3. HYPERCOAGULABILITY (VTE risk 25-40x normal)                     │   │
│   │    • Loss of anticoagulants (Antithrombin III, Protein C/S)        │   │
│   │    • Hepatic synthesis ↑ (Fibrinogen, Factor V, VIII, vWF)         │   │
│   │    • Platelet hyperaggregability                                   │   │
│   │    • Hemoconcentration and hyperviscosity                          │   │
│   │                                                                     │   │
│   │ 4. IMMUNODEFICIENCY                                                 │   │
│   │    • Loss of immunoglobulins (IgG)                                 │   │
│   │    • Loss of complement factors (Factor B, properdin)              │   │
│   │    • Encapsulated organism risk (S. pneumoniae, H. influenzae)    │   │
│   │                                                                     │   │
│   │ 5. ENDOCRINE/METABOLIC                                              │   │
│   │    • Hypothyroidism (loss of thyroid-binding globulin)             │   │
│   │    • Vitamin D deficiency (loss of vitamin D binding protein)      │   │
│   │    • Hypocalcaemia (secondary to vitamin D deficiency)             │   │
│   │    • Trace element deficiency (zinc, copper)                       │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

Podocyte Injury: The Final Common Pathway

Regardless of the underlying cause, podocyte injury with foot process effacement is the hallmark finding on electron microscopy in nephrotic syndrome. [10]

Key molecular mechanisms:

• Cytokines: Circulating permeability factors (especially in minimal change disease and recurrent FSGS post-transplant) [11]
• Autoantibodies: Anti-PLA2R antibodies in membranous nephropathy (70-80% of primary cases) [12]
• Genetic mutations: Podocin (NPHS2), nephrin (NPHS1), TRPC6, INF2 in familial FSGS [13]
• Toxins: Direct podocyte injury from drugs, viruses (HIV, Parvovirus B19), obesity-related hyperfiltration [14]

---

3. Causes and Classification

The differential diagnosis of nephrotic syndrome varies significantly by age, ethnicity, and geographical location. [15]

Primary Glomerular Diseases (Idiopathic)

Image: Comparative Histopathology

Image

1. Minimal Change Disease (MCD) [16,17]

Pathophysiology:

• Mechanism incompletely understood
• Proposed circulating permeability factor (possibly cytokines from activated T-cells)
• Direct podocyte cytoskeletal injury without immune deposits
• Hallmark: Diffuse foot process effacement on EM with normal light microscopy

Clinical features:

• Selectivity: Highly selective proteinuria (predominantly albumin, minimal globulin loss)
• Sudden onset, often after viral infection or vaccination
• Strong association with atopy (asthma, eczema) in children
• Nephrotic range proteinuria (often > 10-15g/day)

Associations:

• Hodgkin's lymphoma (paraneoplastic syndrome)
• NSAIDs (especially in elderly)
• Interferon therapy

Treatment:

• First-line: High-dose corticosteroids (1 mg/kg/day prednisone, max 80mg)
• Response rate: > 90% achieve complete remission
• Time to remission: Usually 4-8 weeks (steroid-sensitive)
• Relapse management:
  • "Frequent relapses (≥2 in 6 months): Consider steroid-sparing agents (cyclophosphamide, tacrolimus, rituximab)"
  • "Steroid-dependent: Calcineurin inhibitors (tacrolimus, cyclosporine)"

Prognosis:

• Excellent for renal function (does NOT progress to ESRD)
• High relapse rate (40-50%), but each relapse responds to steroids
• Quality of life impact from relapses and steroid side effects

2. Focal Segmental Glomerulosclerosis (FSGS) [18,19]

Pathophysiology:

• Podocyte injury and depletion
• Sclerosis (scarring) affecting some glomeruli (focal) and only parts of affected glomeruli (segmental)
• Maladaptive response to podocyte loss

Subtypes (Columbia classification):

• Collapsing variant: Worst prognosis, associated with HIV, genetic mutations (APOL1 in African ancestry)
• Tip variant: Best prognosis, may respond to steroids
• Perihilar variant: Associated with hyperfiltration (obesity, reduced nephron mass)
• Cellular variant: Hypercellularity with sclerosis
• NOS (not otherwise specified): Classic presentation

Primary vs Secondary:

Treatment:

• Conservative management: RAAS blockade (ACEi/ARB), dietary sodium restriction
• Immunosuppression (primary FSGS only):
  • High-dose steroids (1 mg/kg/day) for 4-6 months minimum
  • "Response rate: Only 20-40% achieve complete or partial remission"
  • "Steroid-resistant: Consider calcineurin inhibitors (cyclosporine, tacrolimus)"
  • "Collapsing variant: May try cyclophosphamide or rituximab"

Prognosis:

• Poor: 40-50% progress to ESRD within 5-10 years
• Recurrence post-transplant: 30-50% (especially if rapid progression to ESRD)
• Collapsing variant has worst prognosis (ESRD within 2-3 years)

3. Membranous Nephropathy (MN) [20,21,22]

Pathophysiology:

• In-situ immune complex formation: Autoantibodies bind to podocyte antigens
• Primary MN (75-80% of cases): Anti-PLA2R antibodies (70-80% of primary cases)
  • "Secondary antibodies: Anti-THSD7A (2-5%), Anti-NELL1 (5-10%)"
• Secondary MN (20-25%): Hepatitis B, SLE, malignancy, drugs (NSAIDs, gold, penicillamine)
• Subepithelial immune deposits → Basement membrane "spikes" growing between deposits

Clinical features:

• Age > 40 years (mean age 50-60)
• Gradual onset
• Proteinuria variable (3.5-10g/day)
• Highest thrombosis risk among glomerulopathies (25-35% develop VTE)
• Hypertension in 30-50%

Diagnosis:

• Serology: Anti-PLA2R antibodies highly specific (> 95%) for primary MN
  • Titer correlates with disease activity and treatment response
• Renal biopsy:
  • Light microscopy: Thickened GBM with "spikes on silver stain"
  • "EM: Subepithelial electron-dense deposits (Stages I-IV)"
  • "IF: Granular IgG (predominantly IgG4) + C3"

Natural history ("Rule of Thirds"): [23]

• 1/3: Spontaneous complete or partial remission (within 2 years)
• 1/3: Persistent stable proteinuria without progression
• 1/3: Progressive decline in renal function → ESRD

Risk stratification for treatment decision:

• High risk (treat with immunosuppression):
  • Proteinuria > 4g/day sustained for > 6 months despite conservative therapy
  • Declining GFR
  • High anti-PLA2R titers
• Low risk (conservative management):
  • Proteinuria less than 3.5g/day
  • Stable GFR
  • Low or absent anti-PLA2R antibodies

Treatment: [24]

Conservative phase (6 months):

• Optimize RAAS blockade (ACEi + ARB if tolerated)
• Sodium restriction
• Statin therapy
• Thromboprophylaxis if albumin less than 25 g/L

Immunosuppression (if high risk):

• First-line: Rituximab (two 1g doses, 2 weeks apart)
  • "MENTOR trial (2019): Rituximab non-inferior to cyclosporine for remission, superior for sustained remission [25]"
  • "Complete remission rate: 35-40% at 12 months"
  • "Partial remission: Additional 25-30%"
• Alternative: Cyclical cyclophosphamide + steroids (Ponticelli regimen)
  • "Month 1,3,5: Methylprednisolone"
  • "Month 2,4,6: Cyclophosphamide"
  • Higher toxicity than rituximab, now second-line

Prognosis:

• If achieve complete remission: less than 5% progress to ESRD
• If persistent nephrotic syndrome: 40-50% → ESRD over 10-15 years
• Recurrence post-transplant: 10-15%

Secondary Causes of Nephrotic Syndrome [26]

Diabetic Nephropathy

• Most common cause of nephrotic syndrome in adults worldwide
• Progression: Microalbuminuria → Macroalbuminuria → Nephrotic-range proteinuria
• Histology: Kimmelstiel-Wilson nodular glomerulosclerosis, GBM thickening
• Diagnosis: Often clinical if long-standing diabetes + retinopathy (biopsy not needed)
• Treatment: SGLT2 inhibitors + ACEi/ARB (immunosuppression NOT indicated)

Systemic Lupus Erythematosus (SLE)

• Lupus nephritis Class V (membranous lupus nephritis)
• May occur with or without proliferative component (Class III/IV)
• Positive ANA, anti-dsDNA, low C3/C4
• Treatment: Mycophenolate mofetil or cyclophosphamide + steroids

Amyloidosis

• AL amyloid (light chain): Associated with multiple myeloma/plasma cell dyscrasia
• AA amyloid: Secondary to chronic inflammation (RA, IBD, chronic infections)
• Histology: Apple-green birefringence on Congo red stain
• Diagnosis: Serum/urine protein electrophoresis, serum free light chains
• Kidney + cardiac + neurologic involvement typical

Infections

• Hepatitis B: Membranous nephropathy (especially in children in endemic areas)
• Hepatitis C: MPGN pattern with cryoglobulinemia
• HIV: Collapsing FSGS (HIVAN), especially in patients of African descent with APOL1 risk alleles
• Syphilis: Membranous nephropathy (secondary syphilis)

Drugs

• NSAIDs: Minimal change disease (especially in elderly)
• Gold, penicillamine: Membranous nephropathy
• Heroin: FSGS (often collapsing variant)
• Bisphosphonates: FSGS
• Interferon: Minimal change or FSGS

Malignancy (Paraneoplastic)

• Membranous nephropathy: Solid organ tumors (lung, colon, breast, prostate, stomach)
  • Consider malignancy screening in patients > 60 years with new membranous nephropathy
• Minimal change: Hodgkin's lymphoma
• AL amyloid: Multiple myeloma

Image: Nephrotic Edema

Image

---

4. Clinical Presentation

History

Chief Complaint

• Swelling/Oedema (most common presenting symptom, 85-90% of cases)
• Frothy urine (classic sign of heavy proteinuria)
• Weight gain (fluid retention)
• Reduced urine output
• Fatigue

Detailed History

Onset and progression:

• Gradual vs sudden onset (MCD often sudden, MN gradual)
• Duration of symptoms
• Timing of swelling (worse in morning = periorbital; worse in evening = lower limb)

Associated symptoms:

• Systemic features: Fever, rash, joint pain (suggest secondary cause like SLE)
• Urinary: Hematuria (uncommon in pure nephrotic syndrome; suggests nephritic component)
• Oliguria: May indicate severe hypoalbuminemia or AKI
• Dyspnea: Pulmonary edema, pleural effusion, or pulmonary embolism

Past medical history:

• Diabetes mellitus (diabetic nephropathy)
• Autoimmune diseases (SLE, RA)
• Malignancy (paraneoplastic glomerulopathy)
• HIV, Hepatitis B/C (secondary causes)
• Previous episodes of nephrotic syndrome (MCD relapses)

Medication history:

• NSAIDs (MCD, membranous)
• Gold, penicillamine (membranous)
• Heroin/drug use (FSGS)

Family history:

• Familial FSGS (genetic forms)
• Kidney disease
• Autoimmune conditions

Social history:

• IV drug use (HIV-associated nephropathy, Hepatitis B/C)
• Travel history (infectious etiologies)
• Tobacco (cardiovascular risk assessment)

Physical Examination

General Appearance

• Ill-appearing vs well-appearing (MCD patients often look well despite severe proteinuria)
• Cushingoid features (if previously treated with steroids)

Vital Signs

• Blood pressure: Hypertension common in FSGS and membranous (30-50%), rare in MCD (less than 10%)
• Weight: Establish dry weight baseline for monitoring

Inspection

• Periorbital edema: Prominent on waking (loose tissue allows fluid accumulation)
• Anasarca: Generalized body swelling in severe cases
• Ascites: Abdominal distension with fluid wave
• Pleural effusions: Dullness to percussion, reduced breath sounds

Palpation

• Pitting edema:
  • Lower extremities (ankles, shins) - gravity dependent
  • Sacral area if bed-bound
  • Grade severity (1+ to 4+)
• Assess for DVT: Unilateral swelling, warmth, tenderness (high index of suspicion in nephrotic syndrome)

Specific Signs

Muehrcke's lines:

• Paired white horizontal bands on nail beds
• Due to hypoalbuminemia (less than 25 g/L)
• Disappear when albumin normalized

Xanthelasma and xanthomas:

• Cholesterol deposits around eyelids and tendons
• Due to severe hyperlipidemia

Signs of underlying disease:

• Malar rash, photosensitivity, arthritis: SLE
• Diabetic retinopathy: Diabetic nephropathy
• Lymphadenopathy, hepatosplenomegaly: Lymphoma, amyloid
• Macroglossia, periorbital purpura: AL amyloidosis

---

5. Investigations

Diagnostic Algorithm

┌─────────────────────────────────────────────────────────────────────────────┐
│                    NEPHROTIC SYNDROME DIAGNOSTIC PATHWAY                    │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   STEP 1: CONFIRM NEPHROTIC SYNDROME                                        │
│   ├── Urine dipstick: ++++ Protein                                          │
│   ├── Urine protein:creatinine ratio (uPCR): > 300 mg/mmol                   │
│   │    (or 24h urine protein > 3.5 g/day)                                    │
│   ├── Serum albumin: less than 30 g/L                                                │
│   ├── Serum cholesterol: Usually > 7 mmol/L                                  │
│   └── Assess renal function (creatinine, eGFR)                              │
│                                    ↓                                        │
│   STEP 2: SCREEN FOR SECONDARY CAUSES ("NEPHROTIC SCREEN")                  │
│   ├── Blood glucose/HbA1c ────────────► Diabetes                            │
│   ├── ANA, anti-dsDNA, C3/C4 ─────────► SLE                                 │
│   ├── Hepatitis B surface antigen ────► HBV-associated MN                   │
│   ├── Hepatitis C antibody ───────────► HCV-associated MPGN/cryoglob       │
│   ├── HIV test ───────────────────────► HIV-associated nephropathy (FSGS)  │
│   ├── Serum + urine protein electrophoresis ──► Myeloma/amyloid            │
│   ├── Serum free light chains ────────► AL amyloid                          │
│   ├── Anti-PLA2R antibodies ───────────► Primary membranous nephropathy    │
│   └── Consider: Malignancy screening (age > 60 with membranous)             │
│                                    ↓                                        │
│   STEP 3: RENAL BIOPSY (for histological diagnosis)                         │
│   ├── ADULTS: Mandatory in virtually all cases                              │
│   │    Exceptions:                                                          │
│   │    • Diabetic nephropathy (if long-standing DM + retinopathy)           │
│   │    • Amyloid proven elsewhere                                           │
│   │    • Contraindications to biopsy                                        │
│   │                                                                          │
│   ├── CHILDREN: NOT routine                                                 │
│   │    • Assume MCD, treat empirically with steroids                        │
│   │    • Biopsy only if:                                                    │
│   │      - Age less than 1 year or > 10 years                                         │
│   │      - Steroid-resistant (no remission after 4-8 weeks)                 │
│   │      - Atypical features (hematuria, hypertension, renal impairment)    │
│   │                                                                          │
│   └── Biopsy samples for:                                                   │
│        • Light microscopy (routine stains + silver, PAS, trichrome)         │
│        • Immunofluorescence (IgG, IgM, IgA, C3, C1q, kappa, lambda)        │
│        • Electron microscopy (location of deposits, foot processes)         │
│                                    ↓                                        │
│   STEP 4: ASSESS COMPLICATIONS                                              │
│   ├── Thromboembolism risk:                                                 │
│   │    • D-dimer (often elevated, low specificity)                          │
│   │    • Consider venous duplex if clinical suspicion DVT                   │
│   ├── Infection risk:                                                       │
│   │    • Immunoglobulin levels (IgG often low)                              │
│   ├── AKI screening:                                                        │
│   │    • Creatinine trend                                                   │
│   │    • Urinalysis for casts (granular = ATN; waxy = chronic)             │
│   └── Vitamin D status, bone profile (hypocalcemia)                         │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

Initial Laboratory Tests

Urine Studies

Urinalysis:

• Proteinuria: 3+ to 4+ on dipstick
• Absence of hematuria (if present, consider mixed nephritic-nephrotic picture)
• Microscopy: Oval fat bodies, fatty casts (pathognomonic but insensitive)

Quantification of proteinuria:

• Urine protein:creatinine ratio (uPCR): > 300-350 mg/mmol (> 3-3.5 g/g)
  • More convenient than 24h collection
  • First morning void preferred
• 24-hour urine protein: > 3.5 g/24h (gold standard definition)
  • Often 5-15 g/day in MCD
  • May reach 20-30 g/day in severe cases

Selective proteinuria index (rarely done now):

• Ratio of IgG clearance to albumin clearance
• less than 0.1 = highly selective (suggests MCD)

• 0.2 = non-selective (FSGS, membranous)

Blood Tests

Renal function:

• Creatinine, eGFR
• Urea
• Electrolytes (hyponatremia common from dilution)

Albumin and protein:

• Serum albumin less than 30 g/L (often less than 20 g/L in severe cases)
• Total protein usually low

Lipid profile:

• Total cholesterol elevated (often > 7-10 mmol/L)
• LDL cholesterol markedly elevated
• Triglycerides elevated
• HDL may be low or normal

Hemostasis:

• Antithrombin III levels (often decreased, especially if less than 20 g/L albumin)
• Fibrinogen (often elevated due to hepatic synthesis)

Thyroid function:

• May show "sick euthyroid" pattern
• True hypothyroidism may occur (loss of thyroid-binding globulin)

Etiological Workup ("Nephrotic Screen")

Imaging

Renal ultrasound:

• Assess kidney size (normal or enlarged in acute nephrotic syndrome)
• Rule out obstruction
• Assess for thrombosis (doppler)
• Pre-biopsy assessment

Chest X-ray:

• Pleural effusions
• Pulmonary edema
• Exclude malignancy (if membranous nephropathy)

Echocardiography (if indicated):

• Pericardial effusion
• Cardiac function if volume overloaded

CT chest/abdomen/pelvis (if membranous nephropathy in age > 60):

• Malignancy screening (lung, colon, prostate, kidney)
• 10-15% of membranous cases in elderly are paraneoplastic

Renal Biopsy [27]

Indications in adults:

• ALL adults with new-onset nephrotic syndrome (unless clear diabetic nephropathy or contraindication)
• Guides specific treatment (MCD vs FSGS vs membranous have different therapies)

Indications in children:

• NOT routine (empiric steroid trial for presumed MCD)
• Biopsy if:
  • Age less than 1 year or > 10 years
  • Steroid-resistant (no remission after 8 weeks of prednisone)
  • "Atypical features: Hematuria, hypertension, impaired renal function, low C3"

Contraindications:

• Uncontrolled hypertension
• Bleeding diathesis or anticoagulation (relative)
• Single functioning kidney (relative)
• Uncooperative patient

Biopsy Processing:

Classic biopsy findings:

---

6. Management

Management of nephrotic syndrome has two components: (1) General supportive measures for all patients, and (2) Disease-specific immunosuppression based on biopsy diagnosis. [28]

General Principles

Goals of therapy:

1. Reduce proteinuria
2. Control edema
3. Prevent complications (thromboembolism, infection, cardiovascular disease)
4. Preserve renal function
5. Induce remission of underlying disease (if possible)

Definitions of treatment response:

• Complete remission: uPCR less than 50 mg/mmol (or less than 0.3 g/day) with normal albumin
• Partial remission: uPCR less than 300 mg/mmol (or less than 3.5 g/day) with ≥50% reduction from baseline
• Treatment failure: less than 50% reduction in proteinuria after adequate trial

┌─────────────────────────────────────────────────────────────────────────────┐
│                    NEPHROTIC SYNDROME MANAGEMENT FRAMEWORK                  │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   TIER 1: GENERAL SUPPORTIVE MEASURES (ALL PATIENTS)                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │ 1. FLUID AND SODIUM MANAGEMENT                                      │   │
│   │    • Dietary sodium restriction: less than 2g/day (90 mmol/day)              │   │
│   │    • Fluid restriction only if severe hyponatremia                  │   │
│   │    • Daily weights to monitor fluid status                          │   │
│   │    • Target: Gradual weight loss 0.5-1 kg/day max                   │   │
│   │                                                                     │   │
│   │ 2. DIURETIC THERAPY                                                 │   │
│   │    First-line: Loop diuretics (Furosemide)                          │   │
│   │    • Start: 40-80 mg PO daily                                       │   │
│   │    • Titrate: May need 160-240 mg/day in divided doses              │   │
│   │    • IV route if gut edema impairs absorption                       │   │
│   │                                                                     │   │
│   │    Diuretic resistance strategies:                                  │   │
│   │    • Add thiazide (Metolazone 2.5-5 mg) for synergistic effect     │   │
│   │    • Increase loop diuretic dose                                    │   │
│   │    • Switch to IV administration                                    │   │
│   │    • Albumin infusion + furosemide (rarely used, controversial)    │   │
│   │                                                                     │   │
│   │ 3. RAAS BLOCKADE (reduce proteinuria + renoprotection)             │   │
│   │    • ACEi (Ramipril 5-10 mg/day) OR ARB (Losartan 50-100 mg/day)   │   │
│   │    • Can reduce proteinuria by 30-50%                               │   │
│   │    • Combination ACEi+ARB controversial (KDIGO no longer recommends)│   │
│   │    • Monitor potassium and creatinine                               │   │
│   │    • Contraindicated in pregnancy                                   │   │
│   │                                                                     │   │
│   │ 4. LIPID MANAGEMENT                                                 │   │
│   │    • Statin therapy (Atorvastatin 20-40 mg/day)                     │   │
│   │    • Target LDL less than 2.6 mmol/L (or less than 1.8 if high CV risk)              │   │
│   │    • Long-term CV risk reduction                                    │   │
│   │                                                                     │   │
│   │ 5. DIETARY PROTEIN                                                  │   │
│   │    • Normal protein intake (0.8-1.0 g/kg/day)                       │   │
│   │    • Do NOT restrict protein (no benefit, risks malnutrition)       │   │
│   │    • Do NOT increase protein (worsens proteinuria)                  │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
│   TIER 2: THROMBOEMBOLISM PROPHYLAXIS (CRITICAL)                            │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │ VTE RISK ASSESSMENT                                                 │   │
│   │ • Risk 25-40x higher than general population                        │   │
│   │ • Highest in membranous nephropathy (35% cumulative risk)           │   │
│   │ • Mechanism: Loss of AT-III, Protein C/S; ↑ fibrinogen, factors    │   │
│   │                                                                     │   │
│   │ INDICATIONS FOR THROMBOPROPHYLAXIS:                                 │   │
│   │ ✓ Albumin less than 20-25 g/L (strongest predictor)                          │   │
│   │ ✓ Membranous nephropathy (any albumin level)                        │   │
│   │ ✓ Proteinuria > 10 g/day                                             │   │
│   │ ✓ Additional risk factors (immobility, BMI > 35, prior VTE)          │   │
│   │                                                                     │   │
│   │ PROPHYLACTIC ANTICOAGULATION:                                       │   │
│   │ • LMWH: Enoxaparin 40 mg SC daily (or Dalteparin 5000 units)       │   │
│   │ • Continue until: Albumin > 25-30 g/L AND remission achieved         │   │
│   │                                                                     │   │
│   │ THERAPEUTIC ANTICOAGULATION (if VTE occurs):                        │   │
│   │ • LMWH therapeutic dose OR                                          │   │
│   │ • Warfarin (INR 2-3) - note: may need higher doses due to low alb  │   │
│   │ • DOACs (apixaban, rivaroxaban): Use caution, limited data         │   │
│   │ • Duration: Minimum 3-6 months, consider indefinite if persistent NS│   │
│   │                                                                     │   │
│   │ SPECIAL THROMBOTIC COMPLICATIONS:                                   │   │
│   │ • Renal vein thrombosis (10-15% membranous): Flank pain, hematuria │   │
│   │ • Pulmonary embolism (major cause of mortality)                     │   │
│   │ • Arterial thrombosis (rare but described)                          │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
│   TIER 3: INFECTION PROPHYLAXIS                                             │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │ • Pneumococcal vaccination (PCV13 + PPSV23)                         │   │
│   │ • Annual influenza vaccination                                      │   │
│   │ • Consider PJP prophylaxis if on high-dose steroids + other IS      │   │
│   │ • Low threshold for antibiotics with infections                     │   │
│   │ • Avoid live vaccines if on immunosuppression                       │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
│   TIER 4: DISEASE-SPECIFIC IMMUNOSUPPRESSION                                │
│   (See detailed protocols below for each glomerulopathy)                    │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

Disease-Specific Immunosuppressive Therapy

Minimal Change Disease [29,30]

First-line treatment:

INDUCTION (Adults):
• Prednisone 1 mg/kg/day (maximum 80 mg/day) OR
• Prednisolone 1 mg/kg/day
• Duration: Continue for 4-8 weeks or until complete remission

TAPERING:
• Once remission achieved: Taper over 6 months
• Example: Reduce by 10 mg every 2 weeks

Expected response:
• 90-95% achieve complete remission
• Median time to remission: 4-8 weeks (slower in adults than children)
• 10% may take up to 16 weeks (steroid-sensitive but slow responders)

Relapsing disease:

• Frequent relapses (≥2 relapses in 6 months while on therapy):
  • Continue steroids at lowest dose that maintains remission
  • Add steroid-sparing agent
• Steroid-dependent (relapses when steroids tapered):
  • Add steroid-sparing agent

Steroid-sparing agents:

Rituximab emerging as preferred steroid-sparing agent: [31]

• Fewer long-term toxicities than cyclophosphamide or calcineurin inhibitors
• Particularly useful in children and young adults (preserves fertility)
• May need repeat dosing for sustained remission

Steroid-resistant MCD (rare, less than 5-10%):

• Confirm diagnosis with repeat biopsy (may have missed FSGS)
• Calcineurin inhibitors (cyclosporine or tacrolimus) for 6 months
• Consider cyclophosphamide or rituximab if CNI fails

Focal Segmental Glomerulosclerosis (FSGS) [32,33]

Conservative management (ALL patients):

• Maximize RAAS blockade (ACEi/ARB)
• Sodium restriction
• Diuretics for edema
• Statin therapy

Immunosuppression (PRIMARY FSGS only, not secondary):

FIRST-LINE: High-dose corticosteroids
• Prednisone 1 mg/kg/day (max 80 mg) OR alternate-day dosing
• Duration: MINIMUM 4-6 months before declaring steroid-resistant
  - MCD responds in 4-8 weeks
  - FSGS may take 4-6 months (slow responders)
• Taper: Once remission achieved, taper over 6-12 months

Response rates:
• Complete remission: 20-30%
• Partial remission: Additional 20-30%
• Steroid-resistant: 40-60%

TIP variant: Best response to steroids (60-70% remission)
Collapsing variant: Worst response (less than 10% remission)

Steroid-resistant FSGS:

Key principle:

• If no response after 6-12 months of immunosuppression → Stop (risk >> benefit)
• Focus on conservative management to slow progression

Special considerations:

• Collapsing FSGS: Consider cyclophosphamide or rituximab (steroids alone ineffective)
• Genetic FSGS: Immunosuppression NOT effective (supportive care only)
• Post-transplant recurrence: Plasmapheresis + rituximab (limited efficacy)

Membranous Nephropathy [34,35]

Risk stratification FIRST (determines who needs immunosuppression):

LOW RISK (Conservative management only):

• Proteinuria less than 3.5 g/day
• Stable GFR
• Low/negative anti-PLA2R antibodies
• ~30% chance spontaneous remission

HIGH RISK (Consider immunosuppression):

• Proteinuria > 4 g/day sustained > 6 months despite conservative therapy
• Declining GFR
• High anti-PLA2R antibody titers
• Symptomatic nephrotic syndrome

Conservative phase (6 months, ALL patients):

• Optimize RAAS blockade (ACEi ± ARB)
• Sodium restriction less than 2g/day
• Statin therapy
• Thromboprophylaxis if albumin less than 25 g/L
• Monitor monthly: uPCR, albumin, creatinine

Immunosuppression (if high risk after 6-month conservative trial):

FIRST-LINE: Rituximab [36]

Dosing options:
1. Standard lymphoma protocol: 375 mg/m² IV weekly x 4 weeks
2. RA protocol (preferred): 1000 mg IV on days 0 and 14

Monitoring:
• Anti-PLA2R antibodies every 3 months (titer predicts remission)
• CD19+ B cell counts (expect depletion)
• Proteinuria and albumin monthly

Response:
• Complete remission: 35-40% at 12 months, 60% at 24 months
• Partial remission: Additional 25-30%
• Time to remission: Slow (median 6-12 months)

Predictors of response:
• Decline in anti-PLA2R titer (immunological remission precedes clinical)
• Lower baseline proteinuria
• Preserved GFR at treatment initiation

Relapse:
• Occurs in ~20% after remission
• Re-treat with rituximab if anti-PLA2R rises

ALTERNATIVE: Cyclical cyclophosphamide-steroid (Ponticelli regimen)

• Month 1, 3, 5: IV methylprednisolone 1g x 3 days, then oral prednisone 0.5 mg/kg/day
• Month 2, 4, 6: Oral cyclophosphamide 2 mg/kg/day

Efficacy:
• Complete + partial remission: 60-70%
• Long-term renal survival benefit demonstrated

Toxicity:
• Gonadal toxicity (infertility risk)
• Hemorrhagic cystitis
• Malignancy (bladder cancer, lymphoma)
• Infection

Current use: Second-line (rituximab preferred due to better safety profile)

SECOND-LINE (if rituximab fails or contraindicated):

• Calcineurin inhibitors (cyclosporine, tacrolimus)
  • Response rate 60-80%, but high relapse rate when stopped
  • Use for 6-12 months
• ACTH (adrenocorticotropic hormone): Expensive, limited availability

Secondary membranous nephropathy:

• Treat underlying cause:
  • "Hepatitis B: Antiviral therapy"
  • "Malignancy: Treat cancer"
  • "SLE: Standard lupus therapy (MMF or cyclophosphamide + steroids)"
  • "Drugs: Discontinue offending agent"

Monitoring treatment response:

• Anti-PLA2R antibodies are best predictor
  • Decline = good response likely
  • Persistent high titers = treatment failure likely
• Proteinuria lags behind immunological response by 6-12 months

Diabetic Nephropathy

NOT treated with immunosuppression

MANAGEMENT:
• Glycemic control: HbA1c target less than 7% (individualize)
• Blood pressure control: less than 130/80 mmHg
• RAAS blockade: ACEi or ARB (even if normotensive if proteinuric)
• SGLT2 inhibitors: Dapagliflozin, empagliflozin
  - Reduce proteinuria, slow GFR decline
  - Cardiovascular and renal outcome benefit proven
• GLP-1 agonists: If inadequate glycemic control
• Statin therapy
• Dietary sodium restriction

NO role for steroids or other immunosuppression

Amyloidosis

AL amyloid (primary, light chain):

• Treat underlying plasma cell dyscrasia
• Chemotherapy: Bortezomib-based regimens, autologous stem cell transplant (if eligible)
• Goal: Suppress free light chain production

AA amyloid (secondary):

• Treat underlying inflammatory condition
• Biologics (anti-TNF) for RA, IBD
• Colchicine for familial Mediterranean fever

Special Populations

Pregnancy and Nephrotic Syndrome [37]

Challenges:

• Pre-eclampsia difficult to diagnose (proteinuria already present)
• VTE risk extremely high (pregnancy hypercoagulable + nephrotic syndrome)
• Medication safety concerns

Management modifications:

• Discontinue: ACEi, ARB (teratogenic)
• Switch to: Labetalol, nifedipine, methyldopa for BP control
• Thromboprophylaxis: Essential - therapeutic LMWH throughout pregnancy
• Immunosuppression:
  • "Prednisone: Safe"
  • "Azathioprine: Safe"
  • "Cyclosporine, tacrolimus: Probably safe (limited data)"
  • "Cyclophosphamide, MMF, rituximab: Contraindicated"
• Delivery: Multidisciplinary planning (nephrology, obstetrics, anesthesia)

Elderly Patients

Considerations:

• Higher risk of secondary causes (malignancy-associated membranous, diabetic, amyloid)
• Increased steroid toxicity risk (osteoporosis, diabetes, infections)
• Reduce immunosuppression doses, shorter treatment courses
• Malignancy screening mandatory if membranous nephropathy

Treatment of Complications

Diuretic-Resistant Edema

Strategies:

1. Ensure sodium restriction compliance (most common cause)
2. Increase loop diuretic dose (may need 240-480 mg furosemide daily)
3. Switch to IV administration (bypasses gut edema)
4. Add thiazide for sequential nephron blockade
   • Metolazone 2.5-10 mg
   • Monitor for severe volume depletion and electrolyte abnormalities
5. Consider albumin infusion + furosemide (controversial, expensive, temporary)

Complications of aggressive diuresis:

• Prerenal AKI
• Electrolyte disturbances (hypokalemia, hyponatremia, metabolic alkalosis)
• Intravascular volume depletion despite total body volume overload

Acute Kidney Injury in Nephrotic Syndrome

Causes:

• Prerenal: Over-diuresis, true intravascular volume depletion
• ATN: Severe hypoalbuminemia with renal tubular ischemia
• Interstitial nephritis: Drug-induced (NSAIDs, PPIs)
• Thrombotic: Renal vein thrombosis, bilateral
• Disease progression: FSGS, crescentic component

Management:

• Discontinue nephrotoxins (NSAIDs, aminoglycosides, contrast)
• Cautious volume repletion if prerenal
• Investigate for renal vein thrombosis if sudden deterioration
• May need renal biopsy if diagnosis uncertain

Infection Management

Increased susceptibility due to:

• Loss of immunoglobulins
• Complement deficiency
• Immunosuppressive medications
• Urinary catheterization, central lines

Specific risks:

• Encapsulated bacteria: S. pneumoniae, H. influenzae, N. meningitidis
• Spontaneous bacterial peritonitis: In children with anasarca/ascites
• Opportunistic infections: If on high-dose immunosuppression (PJP, CMV, fungal)

Prophylaxis:

• Vaccinations (pneumococcal, influenza) - give BEFORE immunosuppression if possible
• PJP prophylaxis (trimethoprim-sulfamethoxazole) if on high-dose steroids + other agents
• Low threshold for empiric antibiotics

---

7. Complications

Thromboembolic Complications [38]

Incidence:

• Overall VTE risk: 25-40x higher than general population
• Membranous nephropathy: 35% cumulative incidence
• Renal vein thrombosis: 10-15% in membranous, 5% in other types

Pathophysiology:

• Loss of anticoagulant proteins: Antithrombin III (molecular weight allows urinary loss), Protein C, Protein S
• Increased procoagulant factors: Hepatic synthesis of fibrinogen, Factor V, Factor VIII, von Willebrand factor
• Platelet hyperaggregability
• Hyperviscosity: Hemoconcentration from diuresis
• Impaired fibrinolysis

Clinical presentations:

Deep vein thrombosis (DVT):

• Lower extremity most common
• High index of suspicion for unilateral leg swelling in nephrotic patient
• Diagnosis: Venous duplex ultrasound

Pulmonary embolism (PE):

• Major cause of mortality in nephrotic syndrome
• Dyspnea, chest pain, hemoptysis
• Diagnosis: CTPA (but contrast nephropathy risk - weigh risks/benefits)

Renal vein thrombosis (RVT):

• Acute: Flank pain, hematuria, acute worsening of renal function, LDH elevation
• Chronic: Asymptomatic, may present as resistant proteinuria
• Diagnosis: MRI/MRV (gold standard), doppler ultrasound (less sensitive), CT with contrast
• Bilateral RVT can cause AKI
• Treatment: Anticoagulation (minimum 6 months, often indefinite if persistent nephrotic syndrome)

Arterial thrombosis:

• Rare but reported (coronary, cerebral, peripheral)

Prevention: See thromboprophylaxis section above

Infectious Complications [39]

Mechanisms:

• Loss of IgG and complement factors
• Zinc and vitamin D deficiency (impaired immunity)
• Immunosuppressive medications
• Edema creating fluid collections (ascites → SBP risk)

Common infections:

Bacterial:

• Pneumonia: S. pneumoniae most common
• Cellulitis: In edematous limbs
• Spontaneous bacterial peritonitis: Children with ascites (E. coli, S. pneumoniae)
• Urinary tract infection
• Sepsis

Viral:

• Varicella-zoster reactivation (if on immunosuppression)
• CMV, EBV (high-dose immunosuppression)

Fungal:

• Pneumocystis jirovecii pneumonia (PJP): If on steroids + other agents
• Invasive fungal infections: Rare, severe immunosuppression

Management:

• Low threshold for antibiotics
• Broad-spectrum coverage if septic
• Prophylaxis: See above

Metabolic and Endocrine Complications

Hyperlipidemia:

• Accelerated atherosclerosis
• Long-term cardiovascular risk
• Treatment: Statins (atorvastatin, rosuvastatin)

Vitamin D deficiency and bone disease:

• Loss of vitamin D binding protein
• Secondary hyperparathyroidism
• Osteomalacia (in prolonged nephrotic syndrome)
• Compounded by steroid-induced osteoporosis
• Treatment: Vitamin D supplementation, calcium, bisphosphonates if on steroids

Hypothyroidism:

• Loss of thyroid-binding globulin and thyroid hormones
• Check TSH, free T4 (not total T4, which will be low)
• May need thyroid replacement

Trace element deficiencies:

• Zinc, copper loss (protein-bound)
• May contribute to impaired immunity, growth (children)

Protein-energy malnutrition:

• From dietary protein restriction (no longer recommended)
• Muscle wasting
• Impaired wound healing

Acute Kidney Injury

Causes in nephrotic syndrome:

• Hypovolemia (over-diuresis)
• Acute tubular necrosis (severe hypoalbuminemia, NSAID use)
• Renal vein thrombosis
• Interstitial nephritis (drug-induced)
• Progression of underlying glomerular disease (FSGS, crescentic GN)

Management:

• Identify and treat cause
• Volume assessment and judicious fluid management
• Discontinue nephrotoxins
• May require dialysis if severe

Progression to End-Stage Renal Disease

Risk varies by histology:

Transplant considerations:

• MCD: Excellent outcomes, rare recurrence
• Membranous: Good outcomes, 10-15% recurrence
• FSGS: 30-50% recurrence risk (especially collapsing, rapid progression)
  • Treat recurrence with plasmapheresis + rituximab (limited efficacy)

---

8. Prognosis

Overall Outcomes

Prognosis depends primarily on:

1. Underlying histology (single most important factor)
2. Response to treatment
3. Baseline renal function
4. Degree of tubulointerstitial fibrosis on biopsy
5. Age and comorbidities

Disease-Specific Prognosis

Minimal Change Disease

• Renal survival: Excellent (> 99% preserve renal function long-term)
• Remission rate: > 90% with steroids
• Relapse rate: 40-50% (frequent relapses common)
• Quality of life: Impacted by relapses and steroid toxicity
• Does NOT progress to ESRD

FSGS

• 5-year renal survival: 60-70%
• 10-year renal survival: 50-60%
• If achieve complete remission: > 90% 10-year renal survival
• If partial remission: ~70% 10-year renal survival
• Steroid-resistant with persistent nephrotic syndrome: > 70% → ESRD in 10 years
• Variants: Tip (best), NOS (intermediate), collapsing (worst - ESRD in 2-3 years)

Membranous Nephropathy

"Rule of Thirds" (untreated natural history):

• 1/3: Spontaneous complete or partial remission
• 1/3: Persistent proteinuria without progression
• 1/3: Progressive renal impairment → ESRD

With treatment:

• Complete remission: less than 5% progress to ESRD
• Partial remission: ~15% progress to ESRD over 10 years
• No response to treatment: 50-70% → ESRD over 10-15 years

Anti-PLA2R antibody titers:

• Decline predicts favorable outcome
• Persistent high titers predict treatment failure and progression

Predictors of Poor Renal Outcome (General)

At presentation:

• Elevated creatinine (GFR less than 60 ml/min)
• Severe tubulointerstitial fibrosis on biopsy (> 50%)
• Persistent heavy proteinuria (> 8-10 g/day)
• Hypertension
• Male gender
• Older age

During follow-up:

• Failure to achieve partial or complete remission
• Treatment resistance
• Relapsing disease with steroid dependence

Long-Term Cardiovascular Risk

• Hyperlipidemia and inflammation increase atherosclerosis risk
• Even after remission, CV risk remains elevated
• Long-term statin therapy recommended
• Screen for and manage traditional CV risk factors (hypertension, diabetes, smoking)

Quality of Life

Factors impacting QOL:

• Relapsing disease (MCD)
• Steroid side effects (weight gain, cushingoid features, mood changes, osteoporosis)
• Immunosuppression side effects
• Dietary restrictions (sodium)
• Medication burden
• Psychosocial impact of chronic disease

---

9. Special Considerations

Monitoring During Treatment

Frequency of monitoring depends on disease activity and treatment:

Active nephrotic syndrome:

• Weekly-monthly:
  • "Urine protein:creatinine ratio"
  • Serum albumin
  • Creatinine, eGFR
  • Weight, blood pressure
  • Electrolytes (if on diuretics)

On immunosuppression:

• Steroids: Blood glucose, blood pressure, bone density (if long-term), ophthalmology (cataracts)
• Calcineurin inhibitors: Drug levels (trough), creatinine, electrolytes (hypomagnesemia), lipids
• Cyclophosphamide: CBC (leukopenia), urinalysis (hemorrhagic cystitis)
• Rituximab: IgG levels, CD19+ B cell counts, infection monitoring

In remission:

• Every 3-6 months:
  • "Urine protein:creatinine ratio"
  • Creatinine, eGFR
  • Lipid profile
  • "For membranous: Anti-PLA2R antibodies"

Vaccination

Timing:

• Ideally BEFORE starting immunosuppression (better response)
• If already on immunosuppression, still vaccinate (suboptimal but some protection)

Recommended vaccines:

• Pneumococcal: PCV13, then PPSV23 (8 weeks later)
• Influenza: Annual
• COVID-19: Per current guidelines
• Hepatitis B: If non-immune
• Herpes zoster: Recombinant (Shingrix) - safe even on immunosuppression

Avoid live vaccines if on immunosuppression:

• MMR, varicella, yellow fever, oral typhoid
• Exception: Recombinant zoster vaccine is NOT live (safe)

Drug Dosing Adjustments

Hypoalbuminemia affects drug pharmacokinetics:

• Highly protein-bound drugs have increased free fraction → Increased effect/toxicity
• Examples: Warfarin, phenytoin, diazepam
• May need dose reduction or increased monitoring

Proteinuria causes drug loss:

• Aminoglycosides, vancomycin may need increased doses
• Therapeutic drug monitoring essential

Renal impairment:

• Dose adjustment for renally cleared drugs
• Avoid nephrotoxins (NSAIDs, aminoglycosides, contrast)

Contrast-Induced Nephropathy

Nephrotic patients at increased risk:

• Volume depletion (diuretics)
• Hypoalbuminemia
• Underlying renal impairment

Prevention:

• Hydration (IV 0.9% saline pre- and post-procedure)
• Hold diuretics 24h before
• Use lowest contrast dose possible
• Consider alternative imaging (MRI without gadolinium, ultrasound)

Genetic Counseling

Consider genetic testing if:

• Family history of nephrotic syndrome or FSGS
• Early-onset FSGS (less than 30 years)
• Steroid-resistant nephrotic syndrome in children
• Recurrent FSGS post-transplant
• Consanguinity

Genes associated with nephrotic syndrome:

• NPHS1 (nephrin) - congenital nephrotic syndrome
• NPHS2 (podocin) - steroid-resistant nephrotic syndrome, early-onset FSGS
• TRPC6, ACTN4, INF2 - adult-onset FSGS
• APOL1 - FSGS in African ancestry (G1, G2 risk variants)

Implications:

• Genetic forms do NOT respond to immunosuppression
• Inform family planning decisions
• Predict recurrence risk post-transplant

---

10. Key Clinical Pearls

Diagnostic Pearls

1. Nephrotic vs Nephritic: Nephrotic = Proteinuria dominant. Nephritic = Hematuria + AKI + Hypertension dominant. Some diseases have overlap (MPGN).

2. Frothy urine is pathognomonic for heavy proteinuria - specifically ask about this symptom.

3. Adult with nephrotic syndrome = Biopsy. Exception: Obvious diabetic nephropathy with retinopathy, or contraindication to biopsy.

4. Child with nephrotic syndrome = Treat empirically with steroids for presumed MCD. Biopsy only if atypical or steroid-resistant.

5. Anti-PLA2R antibody is highly specific (> 95%) for primary membranous nephropathy. Negative in secondary membranous (HBV, SLE, malignancy, drugs).

6. Normal glomeruli on light microscopy = Minimal change disease (foot process effacement only visible on EM).

7. Silver stain "spikes" = Membranous nephropathy (GBM projections between subepithelial deposits).

Treatment Pearls

8. Salt restriction is MORE important than fluid restriction - sodium drives water retention via overfill mechanism.

9. High protein diet does NOT help - worsens proteinuria. Normal protein intake (0.8-1.0 g/kg/day).

10. MCD responds to steroids in 4-8 weeks. FSGS may take 4-6 months - don't declare steroid-resistant FSGS too early.

11. Membranous nephropathy: Give 6 months of conservative therapy first before starting immunosuppression (1/3 spontaneously remit).

12. Rituximab is now first-line for membranous nephropathy - MENTOR trial showed non-inferiority to cyclosporine, superior sustained remission, better safety than Ponticelli.

13. Calcineurin inhibitors (cyclosporine, tacrolimus) work quickly but have high relapse rate when stopped - not curative.

14. FSGS: If no response to 6-12 months immunosuppression, STOP - risk outweighs benefit.

Complication Pearls

15. Albumin less than 20 g/L = Extreme VTE risk - strongly consider thromboprophylaxis with LMWH.

16. Membranous nephropathy has highest thrombosis risk among glomerulopathies (35% cumulative incidence).

17. Renal vein thrombosis triad: Flank pain + Hematuria + Acute worsening of renal function. Treat with anticoagulation.

18. Pneumococcal vaccination is ESSENTIAL - loss of IgG and complement → encapsulated organism risk.

19. Diuretic resistance: Add metolazone for sequential nephron blockade - but monitor closely for over-diuresis.

20. Hypothyroidism is common - but check FREE T4, not total T4 (total will be low due to loss of binding protein).

Prognostic Pearls

21. MCD never progresses to ESRD - but relapses are common and quality of life impacted by steroids.

22. FSGS: Achieving remission is KEY - Complete remission = > 90% 10-year renal survival. No remission = > 70% → ESRD.

23. Membranous: "Rule of Thirds" - 1/3 remit, 1/3 stable, 1/3 progress. Anti-PLA2R titer predicts outcome.

24. Tubulointerstitial fibrosis on biopsy is strongest predictor of progression - more than glomerular pathology alone.

25. FSGS recurs in 30-50% of transplants - especially if rapid progression to ESRD originally. Treat with plasmapheresis + rituximab.

---

11. Common Exam Scenarios

OSCE/Clinical Scenarios

Scenario 1: 4-year-old with periorbital swelling

• Diagnosis: Nephrotic syndrome, likely minimal change disease
• Key history: Onset (sudden after URI?), urine appearance (frothy?), recent illnesses/vaccinations
• Examination: Periorbital edema, pitting edema (ankles, sacrum), blood pressure (normal in MCD), signs of infection
• Investigations: Urine dip (proteinuria), uPCR, serum albumin, creatinine
• Management:
  • NO biopsy (assume MCD)
  • Start prednisone 60 mg/m²/day
  • Sodium restriction
  • Pneumococcal vaccination
  • Monitor for complications (infection, VTE)
• Expected outcome: Remission in 4-8 weeks

Scenario 2: 55-year-old man with leg swelling and frothy urine

• Diagnosis: Nephrotic syndrome, adult (need biopsy)
• Key history: Duration, systemic symptoms (cancer screening), diabetes history, medications (NSAIDs?), smoking
• Examination: Pitting edema, blood pressure (may be elevated), xanthelasma, signs of malignancy
• Investigations:
  • "Confirm nephrotic syndrome: uPCR, albumin"
  • "Nephrotic screen: Glucose, ANA, anti-PLA2R, Hep B/C, HIV, SPEP"
  • Renal biopsy (mandatory)
• If biopsy shows membranous:
  • Malignancy screening (CT chest/abdomen/pelvis)
  • 6 months conservative therapy (ACEi, sodium restriction, statin)
  • Thromboprophylaxis (LMWH if albumin less than 25)
  • If persistent high-risk features → Rituximab

Scenario 3: Nephrotic patient with sudden flank pain and hematuria

• Diagnosis: Renal vein thrombosis
• Urgent: Doppler ultrasound or MRI/MRV
• Management: Therapeutic anticoagulation (LMWH → warfarin), continue indefinitely while nephrotic
• Investigate: Why inadequate thromboprophylaxis? Membranous nephropathy?

Scenario 4: Child with nephrotic syndrome not responding to 8 weeks steroids

• Diagnosis: Steroid-resistant nephrotic syndrome
• Action: NOW perform renal biopsy (likely FSGS, not MCD)
• Management: Based on biopsy (likely calcineurin inhibitor)

Viva Voce Questions

Q: How do you differentiate nephrotic from nephritic syndrome? A: Nephrotic syndrome is defined by heavy proteinuria (> 3.5g/24h), hypoalbuminemia (less than 30 g/L), and edema, with hyperlipidemia. Renal function is usually preserved initially. Nephritic syndrome presents with hematuria, hypertension, AKI, and oliguria, with proteinuria being less prominent (typically less than 3.5g/24h). Nephrotic syndrome results from podocyte injury (glomerular filtration barrier damage), while nephritic syndrome results from glomerular inflammation.

Q: Why is there hypercoagulability in nephrotic syndrome? A: Multiple mechanisms: (1) Urinary loss of anticoagulant proteins like antithrombin III, protein C, and protein S; (2) Hepatic overproduction of procoagulant factors (fibrinogen, factor V, VIII, von Willebrand factor); (3) Platelet hyperaggregability; (4) Impaired fibrinolysis; (5) Hemoconcentration from diuresis. The risk is highest when albumin is less than 20 g/L, particularly in membranous nephropathy.

Q: Why biopsy adults but not children? A: In children, minimal change disease accounts for ~90% of cases and has excellent response to steroids (> 90% remission) with virtually no risk of progression to ESRD. Empiric steroid therapy is safe and effective. In adults, the differential is much broader (MCD 10-15%, FSGS 35-40%, membranous 30-40%, secondary causes), and the treatments differ significantly. Biopsy is essential to guide appropriate immunosuppression and prognostication.

Q: Describe the pathophysiology of edema in nephrotic syndrome. A: Two theories: (1) Underfill hypothesis (historical): Heavy proteinuria → hypoalbuminemia → decreased plasma oncotic pressure → fluid shifts to interstitium → intravascular volume depletion → RAAS activation → secondary sodium retention. (2) Overfill hypothesis (now dominant): Primary renal sodium retention occurs via epithelial sodium channel (ENaC) overactivation in the collecting duct, independent of volume status. This explains why many patients are volume expanded with hypertension. Edema is gravity-dependent (periorbital in morning, ankle in evening) and can progress to anasarca.

Q: What is the MENTOR trial and how did it change practice? A: The MENTOR trial (NEJM 2019) compared rituximab versus cyclosporine for the treatment of primary membranous nephropathy. It demonstrated that rituximab was non-inferior for inducing remission and superior for maintaining sustained remission with a better safety profile. This shifted practice from the toxic Ponticelli regimen (cyclical cyclophosphamide + steroids) to rituximab as first-line immunosuppression for high-risk membranous nephropathy.

Q: When would you give thromboprophylaxis in nephrotic syndrome? A: Thromboprophylaxis with LMWH (enoxaparin 40mg daily) is indicated when: (1) Albumin less than 20-25 g/L (strongest predictor); (2) Membranous nephropathy (highest thrombosis risk, ~35% incidence); (3) Proteinuria > 10 g/day; (4) Additional risk factors (immobility, obesity, prior VTE, genetic thrombophilia). Continue until albumin > 25-30 g/L and/or disease remission achieved. If VTE occurs, switch to therapeutic anticoagulation for minimum 3-6 months, often indefinitely while nephrotic.

Q: How does anti-PLA2R antibody help in management? A: Anti-PLA2R (phospholipase A2 receptor) antibody is present in 70-80% of primary membranous nephropathy but negative in secondary causes (HBV, SLE, malignancy), making it highly specific (> 95%) for primary disease. The titer correlates with disease activity: declining titers predict favorable response to treatment and upcoming clinical remission (immunological remission precedes clinical remission by 6-12 months), while persistently high titers predict treatment failure. This allows for monitoring treatment response and predicting relapse.

---

12. Patient Explanation (Layperson)

What is Nephrotic Syndrome?

"Your kidneys work like a very sophisticated filter to clean your blood. Imagine a coffee filter that keeps the coffee grounds in but lets the liquid through. Similarly, your kidney filter is designed to keep important proteins (like albumin) in your blood while filtering out waste products.

In nephrotic syndrome, the kidney filter has become damaged and the holes are too large. This means that albumin - a vital protein that normally stays in your blood - is leaking out into your urine in large amounts.

Albumin acts like a sponge to hold water inside your blood vessels. When you lose too much albumin, water leaks out of your blood vessels into your tissues, causing swelling (edema) - especially around your eyes in the morning and in your ankles by the evening."

Why is my urine frothy?

"The frothy appearance of your urine is due to the large amount of protein being lost. It's similar to egg whites - when protein is mixed with liquid, it becomes foamy. This is actually a very specific sign that helps doctors recognize the condition."

Why do I need a kidney biopsy?

"In adults, there are several different diseases that can damage the kidney filter in different ways:

• Some are caused by an overactive immune system attacking the kidney
• Some are caused by scar tissue forming
• Some are related to diabetes or other conditions

We cannot tell which one you have just from blood tests or urine tests. We need to take a small sample of your kidney tissue (about the size of a grain of rice) to look at under a microscope. This tells us exactly what is causing the problem, which is essential because each type requires different treatment.

In children, we usually don't do a biopsy because the most common cause (minimal change disease) is very treatable with steroids and doesn't harm the kidney long-term."

What is the treatment?

"Treatment has two parts:

1. General measures (for everyone):

• Salt restriction (most important!): You must limit salt to less than 2 grams per day. Salt holds onto water and makes swelling worse. Even water tablets won't work if you eat too much salt.
• Water tablets (diuretics): Help your body get rid of extra fluid
• Blood pressure medication (ACE inhibitors): Helps reduce protein loss
• Cholesterol medication (statins): Your cholesterol is often very high and needs treatment
• Blood thinners: If your albumin is very low (less than 20), you are at very high risk of blood clots, so we may give you injections to prevent this

2. Specific treatment (depends on biopsy result):

• Minimal change disease: Steroid tablets (prednisone). This works in over 90% of people but may take 4-8 weeks. The condition often comes back (relapses), but each time it responds to steroids again.
• FSGS (focal segmental glomerulosclerosis): Steroids for at least 4-6 months. This is harder to treat and may not always work.
• Membranous nephropathy: First, we try 6 months of conservative treatment (salt restriction, blood pressure medication). If that doesn't work, we may use a medication called rituximab, which suppresses the immune system.
• Diabetic kidney disease: Excellent diabetes control, blood pressure control, and new medications called SGLT2 inhibitors. We do NOT use steroids for this."

Will I need dialysis?

"It depends on the type of kidney disease you have:

• Minimal change disease: Almost never progresses to kidney failure. Your kidneys will recover.
• Membranous nephropathy: About 1/3 of people get better on their own, 1/3 stay stable, and 1/3 may slowly worsen. If treatment makes the protein leak stop, your risk of kidney failure is very low.
• FSGS: This is more serious. If the treatment works and stops the protein leak, your kidneys usually do well. If the protein leak continues despite treatment, there is a higher risk of needing dialysis in the future.
• Diabetic kidney disease: Progression can usually be slowed with good control of diabetes and blood pressure."

Can I just drink less water to reduce swelling?

"No, this is a common misconception. The problem is salt, not water.

When you eat salt, your body holds onto water to dilute it. In nephrotic syndrome, your kidneys are particularly sensitive to salt and will retain extra water for every bit of salt you eat.

You must avoid:

• Adding salt to cooking or at the table
• Processed foods (canned soups, frozen meals, deli meats, chips, crackers)
• Restaurant meals (often very high in salt)
• Soy sauce, ketchup, pickles

Read food labels - aim for less than 2000mg (2 grams) of sodium per day total.

Drinking less water won't help the swelling, but eating less salt will."

What are the risks?

"Two main complications we watch for:

1. Blood clots (thrombosis): Your blood becomes 'sticky' because you're losing proteins that normally prevent clotting. This puts you at very high risk of blood clots in your legs (DVT), lungs (pulmonary embolism), or kidneys (renal vein thrombosis).

Warning signs: Sudden leg swelling (especially one-sided), chest pain, difficulty breathing, coughing blood, severe back or flank pain.

If your albumin is very low (less than 20), we will give you blood thinner injections to prevent this.

2. Infections: You're losing antibodies (immune proteins) in your urine, making you more susceptible to infections, especially pneumonia.

You should get:

• Pneumonia vaccine (pneumococcal)
• Annual flu vaccine
• Prompt treatment of any infections

Avoid sick contacts if possible, especially when on steroids or other immune-suppressing medications."

Will this come back after treatment?

"It depends on the type:

• Minimal change disease: Yes, relapses are common (40-50%). You may need multiple courses of steroids over the years. The good news is it always responds to treatment and doesn't damage your kidneys permanently.
• FSGS: If you achieve remission, there's still a 40-60% chance of relapse. Long-term follow-up is important.
• Membranous nephropathy: If you achieve remission, relapse occurs in about 20%. We monitor with blood tests (anti-PLA2R antibody) which can predict if a relapse is coming.

Even after achieving remission, you need regular follow-up with urine and blood tests to catch any relapse early."

Can I have children?

"Pregnancy with nephrotic syndrome is high risk and requires specialized care:

Challenges:

• Very high risk of blood clots (pregnancy itself increases clot risk, combined with nephrotic syndrome is extremely high)
• Difficult to diagnose pre-eclampsia (a dangerous pregnancy complication that also causes protein in urine)
• Some medications must be stopped (ACE inhibitors can harm the baby)

Planning:

• Ideally, achieve remission BEFORE becoming pregnant
• Pre-pregnancy counseling with nephrologist and high-risk obstetrician
• Throughout pregnancy: Daily blood thinner injections, frequent monitoring
• Switch blood pressure medications to pregnancy-safe options
• Multidisciplinary team (nephrology, obstetrics, anesthesia)

With careful planning and monitoring, successful pregnancy is possible, but it requires extensive medical support."

---

13. Evidence & Guidelines

Major Clinical Practice Guidelines

Landmark Clinical Trials

MENTOR Trial (2019) [40]

Full name: Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

Design: Multicenter, open-label, randomized controlled trial

Population: 130 patients with primary membranous nephropathy and nephrotic-range proteinuria

Intervention:

• Rituximab: 1g IV on days 1 and 15
• Cyclosporine: 3.5 mg/kg/day for 12 months, then taper

Results:

• Complete or partial remission at 24 months: Rituximab 60% vs Cyclosporine 20% (Pless than 0.001)
• Rituximab non-inferior for achieving remission, superior for sustained remission
• Fewer adverse events with rituximab

Impact: Changed clinical practice - rituximab is now first-line immunosuppression for membranous nephropathy

FSGS Clinical Trial (FSGS-CT) [41]

Design: Randomized trial comparing cyclosporine vs MMF/dexamethasone

Population: 192 patients with steroid-resistant FSGS

Results:

• Complete + partial remission: Cyclosporine 46% vs MMF/dex 33% (not statistically significant)
• High relapse rate when cyclosporine stopped
• Neither regimen highly effective for steroid-resistant FSGS

Impact: Highlighted difficulty of treating steroid-resistant FSGS, supported use of calcineurin inhibitors as next-line therapy

Ponticelli Regimen [42]

Original studies (1989, 1992): Established cyclical cyclophosphamide-steroid therapy for membranous nephropathy

Results: Demonstrated superior remission rates and renal survival compared to supportive care alone

Impact: Was gold standard for decades, now supplanted by rituximab due to better safety profile

Systematic Reviews and Meta-Analyses

Cochrane Review: Immunosuppressive Treatment for Idiopathic Membranous Nephropathy (2021) [43]

• Analyzed 36 RCTs with 1,527 participants
• Found rituximab and cyclical cyclophosphamide-steroid effective for inducing remission
• Calcineurin inhibitors effective but high relapse rate
• Supported rituximab as first-line based on efficacy and safety

Cochrane Review: Interventions for Minimal Change Disease in Adults (2022) [44]

• Corticosteroids highly effective (> 90% remission)
• Frequent relapses common
• Steroid-sparing agents (rituximab, cyclophosphamide, calcineurin inhibitors) reduce relapse rates
• Rituximab emerging as preferred steroid-sparing agent

Evidence-Based Treatment Recommendations

Emerging Evidence and Controversies

Sparsentan (Dual Endothelin/Angiotensin Receptor Antagonist)

• DUPRO trial (2023): Showed superior proteinuria reduction vs irbesartan in IgA nephropathy
• Ongoing trials in FSGS
• May become new treatment option for proteinuric kidney diseases

Obinutuzumab (Novel Anti-CD20 Antibody)

• Potentially more potent than rituximab
• Under investigation for membranous nephropathy

Anti-CD40 Antibodies

• Targeting B-cell activation without B-cell depletion
• Early-phase trials in membranous nephropathy

Abatacept (CTLA-4 Ig)

• Recurrent FSGS post-transplant: Case reports of efficacy
• Hypothesis: Blocks T-cell derived permeability factor
• Ongoing trials

Genetic Testing

• Debate over role of routine genetic testing in FSGS
• May identify patients unlikely to respond to immunosuppression
• Cost-effectiveness unclear

---

14. References

1. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

2. Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. Am Fam Physician. 2016;93(6):479-485. PMID: 26977831

3. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185-1189. doi:10.1136/bmj.39576.709711.80

4. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52. doi:10.1016/j.kint.2016.02.026

5. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665

6. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997;30(5):621-631. doi:10.1016/s0272-6386(97)90485-6

7. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815-825. PMID: 15492947

8. Kopp JB, Anders HJ, Susztak K, et al. Podocytopathies. Nat Rev Dis Primers. 2020;6(1):68. doi:10.1038/s41572-020-0196-7

9. Scott RP, Quaggin SE. Review series: The cell biology of renal filtration. J Cell Biol. 2015;209(2):199-210. doi:10.1083/jcb.201410017

10. Jefferson JA, Shankland SJ. The pathogenesis of focal segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014;21(5):408-416. doi:10.1053/j.ackd.2014.05.009

11. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878-883. doi:10.1056/NEJM199604043341402

12. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi:10.1056/NEJMoa0810457

13. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502-517. doi:10.2215/CJN.05960616

14. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398-2411. doi:10.1056/NEJMra1106556

15. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.

16. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332-345. doi:10.2215/CJN.05000516

17. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445-453. doi:10.2215/CJN.03531006

18. De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol. 2018;29(3):759-774. doi:10.1681/ASN.2017090958

19. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061-1068. doi:10.1681/ASN.2004070593

20. Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69. doi:10.1038/s41572-021-00303-z

21. Beck LH Jr, Salant DJ. Membranous nephropathy: from models to man. J Clin Invest. 2014;124(6):2307-2314. doi:10.1172/JCI72270

22. Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566-574. doi:10.1016/j.kint.2016.09.048

23. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329(2):85-89. doi:10.1056/NEJM199307083290203

24. van den Brand JA, Hofstra JM, Wetzels JF. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(8):1242-1248. doi:10.2215/CJN.00040112

25. Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi:10.1056/NEJMoa1814427

26. Cattran DC, Feehally J, Cook HT, et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139-274.

27. Hogan JJ, Mocanu M, Berns JS. The Native Kidney Biopsy: Update and Evidence for Best Practice. Clin J Am Soc Nephrol. 2016;11(2):354-362. doi:10.2215/CJN.05750515

28. Kashgary A, Sontrop JM, Li L, et al. The role of engraftment syndrome in renal transplantation: a systematic review. Crit Care. 2017;21(1):277. doi:10.1186/s13054-017-1830-7

29. Palmer SC, Navaneethan SD, Craig JC, et al. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2008;(1):CD001537. doi:10.1002/14651858.CD001537.pub3

30. Shinzawa M, Yamamoto R, Nagasawa Y, et al. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study. Clin J Am Soc Nephrol. 2014;9(7):1189-1194. doi:10.2215/CJN.12331213

31. Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308-1315. doi:10.2215/CJN.09421010

32. Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al. Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. J Am Soc Nephrol. 2017;28(10):3055-3065. doi:10.1681/ASN.2016101121

33. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868-878. doi:10.1038/ki.2011.195

34. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444-450. doi:10.1681/ASN.V93444

35. Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735-1743. doi:10.1681/ASN.2012030242

36. Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563-579. doi:10.1038/nrneph.2017.92

37. Blom K, Odutayo A, Bramham K, Hladunewich MA. Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines. Clin J Am Soc Nephrol. 2017;12(11):1862-1872. doi:10.2215/CJN.00130117

38. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513-520. doi:10.2215/CJN.10131011

39. Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43-51. doi:10.2215/CJN.04250411

40. Fervenza FC, Appel GB, Barbour SJ, et al; MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi:10.1056/NEJMoa1814427

41. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868-878. doi:10.1038/ki.2011.195

42. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48(5):1600-1604. doi:10.1038/ki.1995.453

43. Palmer SC, Sciancalepore M, Strippoli GF. Rituximab and other monoclonal antibodies for idiopathic membranous nephropathy. Cochrane Database Syst Rev. 2021;2(2):CD007485. doi:10.1002/14651858.CD007485.pub3

44. Palmer SC, Navaneethan SD, Craig JC, et al. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2022;2(2):CD001537. doi:10.1002/14651858.CD001537.pub5